Literature DB >> 17344217

MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts.

Jiening Xiao1, Xiaobin Luo, Huixian Lin, Ying Zhang, Yanjie Lu, Ning Wang, Yiqiang Zhang, Baofeng Yang, Zhiguo Wang.   

Abstract

We have previously found that the ether-a-go-go related gene (ERG), a long QT syndrome gene encoding a key K(+) channel (I(Kr)) in cardiac cells, is severely depressed in its expression at the protein level but not at the mRNA level in diabetic subjects. The mechanisms underlying the disparate alterations of ERG protein and mRNA, however, remained unknown. We report here a remarkable overexpression of miR-133 in hearts from a rabbit model of diabetes, and in parallel the expression of serum response factor (SRF), which is known to be a transactivator of miR-133, was also robustly increased. Delivery of exogenous miR-133 into the rabbit myocytes and cell lines produced post-transcriptional repression of ERG, down-regulating ERG protein level without altering its transcript level and caused substantial depression of I(Kr), an effect abrogated by the miR-133 antisense inhibitor. Functional inhibition or gene silencing of SRF down-regulated miR-133 expression and increased I(Kr) density. Repression of ERG by miR-133 likely underlies the differential changes of ERG protein and transcript thereby depression of I(Kr), and contributes to repolarization slowing thereby QT prolongation and the associated arrhythmias, in diabetic hearts. Our study provided the first evidence for the pathological role of miR-133 in adult hearts and thus expanded our understanding of the cellular function and pathophysiological roles of miRNAs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17344217     DOI: 10.1074/jbc.C700015200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  75 in total

1.  Effect of microRNA modulation on bioartificial muscle function.

Authors:  Caroline Rhim; Cindy S Cheng; William E Kraus; George A Truskey
Journal:  Tissue Eng Part A       Date:  2010-08-28       Impact factor: 3.845

2.  miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress.

Authors:  Jiening Xiao; Huixian Lin; Xiaobin Luo; Xiaoyan Luo; Zhiguo Wang
Journal:  EMBO J       Date:  2011-01-07       Impact factor: 11.598

3.  NFATc4 is negatively regulated in miR-133a-mediated cardiomyocyte hypertrophic repression.

Authors:  Qi Li; Xi Lin; Xiangsheng Yang; Jiang Chang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-02-19       Impact factor: 4.733

Review 4.  microRNAs and muscle disorders.

Authors:  Jian-Fu Chen; Thomas E Callis; Da-Zhi Wang
Journal:  J Cell Sci       Date:  2009-01-01       Impact factor: 5.285

5.  microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart.

Authors:  Ning Liu; Svetlana Bezprozvannaya; Andrew H Williams; Xiaoxia Qi; James A Richardson; Rhonda Bassel-Duby; Eric N Olson
Journal:  Genes Dev       Date:  2008-11-17       Impact factor: 11.361

Review 6.  MicroRNA-206: the skeletal muscle-specific myomiR.

Authors:  John J McCarthy
Journal:  Biochim Biophys Acta       Date:  2008-03-12

Review 7.  MicroRNAs: a novel class of potential therapeutic targets for cardiovascular diseases.

Authors:  Zhen-wei Pan; Yan-jie Lu; Bao-feng Yang
Journal:  Acta Pharmacol Sin       Date:  2009-12-07       Impact factor: 6.150

Review 8.  MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets.

Authors:  Eva van Rooij; Eric N Olson
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

9.  MicroRNA-133a regulates DNA methylation in diabetic cardiomyocytes.

Authors:  Vishalakshi Chavali; Suresh C Tyagi; Paras K Mishra
Journal:  Biochem Biophys Res Commun       Date:  2012-07-27       Impact factor: 3.575

10.  The role of microRNA-133 in cardiac hypertrophy uncovered.

Authors:  Maha Abdellatif
Journal:  Circ Res       Date:  2010-01-08       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.